Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis
Compared to usual care, CBD seems to be cost-effective in LGS patients and sustainable, with less than 34% overall budget increased in the next 5 years. Future studies need to confirm our results in the real word setting and in other countries.
Authors
- Zahra Goudarzi (ORCID: https://orcid.org/0000-0002-7096-5276)
- Nasrin Moradi (ORCID: https://orcid.org/0000-0002-5110-2133)
- Mohsen Taghizadeh (ORCID: https://orcid.org/0000-0001-6526-5497)
- Khosro Keshavarz (ORCID: https://orcid.org/0000-0002-5778-5502)
- Farhad Lotfi (ORCID: https://orcid.org/0000-0002-2323-4307)
- Rahil Sadat Shahtaheri
Institutions
- Shiraz University of Medical Sciences (IR)
- Ministry of Health and Medical Education (IR)
Publication Details
- Journal
- BMC Medicine
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1186/s12916-025-03972-9
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00